Borie F, Millat B, Fingerhut A, Hay J M, Fagniez P L, De Saxce B
Service de Chirurgie Viscérale, Hôpital Léon Touhladjian, 10 rue du Champs Gaillard, 78303 Poissy, France.
Arch Surg. 2000 Oct;135(10):1218-23. doi: 10.1001/archsurg.135.10.1218.
The prognosis of early gastric cancer (EGC) is considered better than that of invasive gastric carcinoma, with a 5-year survival rate of more than 90% after surgery. The prevalence of lymph node metastasis in EGC ranges from 8% to 20% and is associated with a poor prognosis.
The main prognostic factor of EGC in patients in France is lymphatic involvement.
DESIGN, SETTING, AND PATIENTS: From January 1979 to December 1988, 332 patients with EGC were operated on in 23 centers of 2 of the French Associations for Surgical Research. Clinical, pathological, and therapeutic data were reviewed, and the reckoning point was in June 1996.
The cumulative 5- and 7-year specific survival rates of EGC with or without lymphatic involvement.
The cumulative 5- and 7-year specific survival rates of 332 patients with EGC (mean follow-up time, 80 months), excluding both operative and unrelated mortality, were 92% and 87.5%, respectively. Thirty-four patients (10.2%) had metastatic lymphatic spread: 13 exclusively in the lymphatic vessels close to the tumor, 17 in at least 1 lymph node, and 4 in both the lymphatic vessels and nodes. The rate of lymph node involvement (regardless of lymphatic vessel involvement) correlated significantly with submucosal invasion (P =. 05) and histologic undifferentiation (P =.03). Lymphatic vessel involvement correlated positively with lymph node involvement (P =. 003). Since 5- and 7-year survival rates of the 13 patients with EGC who had lymphatic vessel involvement without lymph node involvement did not differ significantly from those of patients who had EGC with lymph node involvement (85% and 84% vs 72% and 63%, respectively [P =.42]), all patients with lymph node and/or lymphatic vessel involvement were considered unique. Prognosis was poorest in these patients according to both univariate analysis (94% for 298 without node or vessel involvement vs 78% for 34 with node and/or vessel involvement; P =.006) and multivariate analysis (P =.01). Submucosal invasion was a prognostic factor independent of lymphatic involvement (P =.05). Five- and 7-year survival rates did not differ when the group of 211 patients for whom less than 15 lymph nodes were retrieved were compared with those (n = 51) for whom 15 or more lymph nodes were retrieved (95.5% vs 92% and 95.5% vs 88%, respectively), whether according to univariate (P =.21) or multivariate (P =.31) analysis.
Our results suggest that both lymph node and lymphatic vessel involvement are important prognostic factors in patients with EGC. Lymphadenectomy in EGC is important to identify the high-risk population for whom prognosis is worse. The extent of lymphadenectomy (at least 15 nodes) in these patients, however, does not alter prognosis.
早期胃癌(EGC)的预后被认为优于浸润性胃癌,术后5年生存率超过90%。EGC的淋巴结转移发生率为8%至20%,且与预后不良相关。
法国患者EGC的主要预后因素是淋巴管受累。
设计、地点和患者:1979年1月至1988年12月,法国两个外科研究协会的23个中心对332例EGC患者进行了手术。回顾了临床、病理和治疗数据,计算时间点为1996年6月。
有无淋巴管受累的EGC患者的累积5年和7年特异性生存率。
332例EGC患者(平均随访时间80个月),排除手术和非相关死亡率后,累积5年和7年特异性生存率分别为92%和87.5%。34例患者(10.2%)发生转移性淋巴管扩散:13例仅在肿瘤附近的淋巴管中扩散,17例至少有1个淋巴结转移,4例淋巴管和淋巴结均有转移。淋巴结受累率(无论淋巴管是否受累)与黏膜下浸润(P = 0.05)和组织学未分化(P = 0.03)显著相关。淋巴管受累与淋巴结受累呈正相关(P = 0.003)。13例仅有淋巴管受累而无淋巴结受累的EGC患者的5年和7年生存率与有淋巴结受累的EGC患者相比无显著差异(分别为85%和84% vs 72%和63% [P = 0.42]),因此所有有淋巴结和/或淋巴管受累的患者被视为一个独特群体。根据单因素分析(298例无淋巴结或血管受累患者的生存率为94%,34例有淋巴结和/或血管受累患者的生存率为78%;P = 0.006)和多因素分析(P = 0.01),这些患者的预后最差。黏膜下浸润是独立于淋巴管受累的预后因素(P = 0.05)。当比较211例清扫淋巴结少于15个的患者与51例清扫淋巴结15个或更多的患者时,无论根据单因素分析(P = 0.21)还是多因素分析(P = 0.31),5年和7年生存率均无差异(分别为95.5% vs 92%和95.5% vs 88%)。
我们的结果表明,淋巴结和淋巴管受累都是EGC患者重要的预后因素。EGC患者进行淋巴结清扫对于识别预后较差的高危人群很重要。然而,这些患者的淋巴结清扫范围(至少15个淋巴结)并不能改变预后。